Amgen Inc. (NASDAQ:AMGN) Shares Bought by XTX Topco Ltd

by · The Markets Daily

XTX Topco Ltd raised its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 118.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,127 shares of the medical research company’s stock after purchasing an additional 2,782 shares during the quarter. XTX Topco Ltd’s holdings in Amgen were worth $1,597,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMGN. KPP Advisory Services LLC raised its stake in shares of Amgen by 87.1% in the 1st quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company’s stock valued at $1,817,000 after acquiring an additional 2,716 shares during the period. Advisor Resource Council purchased a new position in shares of Amgen in the 1st quarter valued at $1,331,000. DLK Investment Management LLC raised its stake in shares of Amgen by 7.3% in the 1st quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company’s stock valued at $6,384,000 after acquiring an additional 1,387 shares during the period. Mariner LLC raised its stake in shares of Amgen by 2.2% in the 4th quarter. Mariner LLC now owns 914,380 shares of the medical research company’s stock valued at $238,316,000 after acquiring an additional 19,250 shares during the period. Finally, Nutshell Asset Management Ltd purchased a new position in shares of Amgen in the 4th quarter valued at $2,763,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.76% of the company’s stock.

Amgen Trading Down 2.1%

NASDAQ AMGN opened at $295.10 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $340.89. The company has a 50-day simple moving average of $291.53 and a 200-day simple moving average of $291.66. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The firm has a market capitalization of $158.68 billion, a PE ratio of 26.93, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period in the previous year, the business posted $3.96 EPS. The company’s quarterly revenue was up 9.4% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on AMGN. Mizuho raised their target price on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research note on Wednesday, May 7th. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price on the stock. Citigroup raised their target price on shares of Amgen from $300.00 to $305.00 and gave the company a “neutral” rating in a research note on Tuesday, July 22nd. Bank of America lifted their price target on shares of Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada dropped their price target on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $307.27.

Get Our Latest Research Report on AMGN

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).